Shares of Sharps Technology, Inc. (NASDAQ: STSS) were surging 75.40% to $6.56 as of the last check in recent trading. The momentum followed announcement of its first commercial product shipments under three separate customer orders. These deliveries mark a major transition for STSS from development-focused operations to a revenue-generating commercial enterprise.
Initial Deliveries of Smart Syringes Begin
Sharps Technology commenced its inaugural shipment of SoloGard smart safety syringes under a previously announced $50 million, five-year supply agreement with a U.S.-based leader in IV flushing solutions.
The initial $400,000 order includes customized 10mL SoloGard syringes produced at Sharps Technology’s upgraded manufacturing facility in Hungary. SoloGard syringes feature an FDA- and WHO-approved design with ultra-low waste capability, luer lock compatibility, and single-use safety mechanisms. The order represents STSS’ first revenue-generating delivery under this strategic contract, which may involve up to 500 million units.
Expansion Across Global Healthcare and Cosmetic Markets
In a separate transaction, Sharps fulfilled a $100,000 purchase order for its SecureGard syringes to a Hungarian vaccine provider. SecureGard, also FDA- and WHO-approved and CE Mark-certified, includes advanced safety features such as an active recessed safety system and ultra-low waste design.
Simultaneously, Sharps Technology shipped 200,000 low dead space 1mL syringes to a Swiss-based firm specializing in cosmetic, dental, and ophthalmic injectable therapies. These syringes, intended for use in Botox injection pens, represent the first installment of a 1-million-unit commitment.
Strategic Manufacturing and Global Market Expansion
All products were manufactured at Sharps Technology’s newly enhanced Hungary facility, which now features next-generation molding and automation systems. These upgrades allow for high-precision, scalable production to support both current and future purchase obligations.
Sharps Technology is well-positioned to satisfy the expanding need for cutting-edge safety syringe solutions worldwide by acquiring several foreign clients and moving into active commercial operations. This accomplishment demonstrates STSS’ successful long-term strategic plan execution and its rise to prominence in international healthcare supply chains.
Leave a Reply